Renfu Pharmaceutical (600079.SH) subsidiary withdraws registration application for recombination plasmid - Hepatocyte growth factor injection

Zhtng Cijng APP News, Renfu Medicine (600079.SH) announced that the company's controlling subsidiary, Wuhan Optics Valley Renfu Biopharmaceutical Co., Ltd. (abbreviated as "Optics Valley Renfu", of which the company holds 81.30% equity), recently received a "Drug Registration Application Termination Notice" issued by the National Medical Products Administration, approving Optics Valley Renfu to withdraw the registration application for the recombinant plasmid-liver cell growth factor injection.